

ICMJE DISCLOSURE FORM

Date: 29th November 2022

Your Name: Dr Amanda L Tatler

Manuscript Title: Asthmatic Airway Remodeling: Long Overlooked but Too Important to Ignore

Manuscript number (if known): ATM-22-5733

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Medical Research Council	Research funding as Co-Investigator paid to institution
		Cystic Fibrosis Foundation	Research funding as Co-Investigator paid to institution
		Medical Research Foundation	Funding for training and development paid to institution
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	Pliant Therapeutics	Consultancy fees paid directly to me
		Accession Therapeutics	Consultancy fees paid to institution

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Australian Rare Lung Disease Short course	Fee paid directly to me
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Treasurer, British Association for Lung Research	Unpaid
		Programming Committee, RCMB, American Thoracic Society	Unpaid
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

Dr. Tatler reports funding from Medical Research Council, Cystic Fibrosis Foundation and Medical Research Foundation; consulting fees from Pliant Therapeutics, Accession Therapeutics and Australian Rare Lung Disease Short course. She is treasurer of British Association for Lung Research and programming committee of RCMB and American Thoracic Society.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.